The Oncomine data revealed that the mRNA expression levels of FAM46C were significantly decreased in most cancers, such as bladder, brain and central nervous system, colorectal, stomach, kidney and pancreatic cancers; leukaemia and sarcoma (SARC). Here, TENT5C is linked to leukemia.